Small molecule drug companies develop low-molecular-weight medicines designed to interact with specific biological targets. These compounds can often enter cells and may be formulated as oral or other conventional dosage forms across a wide range of therapeutic areas.
This category includes companies working on:
Browse 202 UK small molecule drug companies below.
Integrated drug development, formulation and Phase I clinical services
Quotient Sciences is a contract research, development and manufacturing organisation providing integrated drug development services to pharmaceutical and biotech companies. Its…
Pre-clinical platelet function testing for drug discovery and safety
Platelet Services is a contract research organisation specialising in pre-clinical platelet function testing for pharmaceutical and biotechnology clients. The company provides…
Intranasal anti-CD3 antibody therapies for neurodegenerative diseases
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapeutics for neurodegenerative and autoimmune diseases. Its lead candidate,…
Antigen modulation therapies for cancer and autoimmune disease
Grey Wolf Therapeutics is a clinical-stage biotechnology company developing small molecule inhibitors of endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2) to modulate…
Small molecule regulators of mitochondrial transfer for age related disease
Nascent Therapeutics is a biotechnology company developing small molecule therapies that regulate mitochondrial transfer between cells. The company's discovery platform identifies…
Custom radiolabelling and integrated small molecule drug discovery services
Eurofins Selcia is a contract research organisation specialising in custom carbon-14 and stable isotope radiolabelling, GMP radiolabelled API manufacturing, and integrated small…
AI-ready toxicity datasets for preclinical drug discovery
Biolligence is a biotechnology company developing AI-ready toxicity datasets and predictive tools for the drug discovery industry. The company combines deep learning algorithms…
DNA damage response platform targeting hard-to-treat solid tumours
Artios Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics that target DNA damage response pathways in cancer cells. The company's pipeline…
Global biopharma with UK R&D centre on the Wirral Peninsula
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company with a long-established UK R&D site at Moreton on the Wirral Peninsula and its UK and Ireland commercial…
Clinical-stage rare disease biotech acquiring deprioritised pharma assets
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases. Founded in 2015, its business model centres on acquiring…
Preclinical CRO for pharmaceutical and agrochemical drug development
Labcorp Early Development Laboratories is a major nonclinical contract research organisation operating from its Harrogate campus in North Yorkshire. The facility provides…
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and…